Table of Contents As filed with the Securities and Exchange Commission on January 9, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number ...

AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic peptides, linear peptides, ascomycin macrolactams, and polyketides—while maintaining a precise sub-20 nm nanoparticle pro ...

Core Insights - Oncotelic Therapeutics Inc. is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the evolving landscape of cancer therapy through innovative drug delivery systems [1][2]. Industry Overview - The global cancer-therapy landscape is rapidly evolving towards precision drug-delivery systems aimed at enhancing efficacy, reducing toxicity, and improving patient outcomes. Traditional treatments face challenges such as low bioavailability and poor tumor targeting, which limit their clinical success [2]. - Breakthroughs in nanomedicine are addressing these challenges, with increasing support from regulatory bodies like the U.S. FDA for nanocarrier-based delivery technologies in advanced therapeutics [2][3]. Company Profile - Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates [4]. - The company utilizes its proprietary Deciparticle(TM) platform to enhance the bioavailability and therapeutic index of existing oncology drugs, potentially redefining cancer treatment standards by improving underutilized compounds [3][4]. - Oncotelic holds a 45% stake in GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, further strengthening Oncotelic's strategic position in oncology and rare disease therapeutics [4].

Core Insights - Oncotelic Therapeutics, Inc. announced that its investigational intravenous Deciparticle everolimus (Sapu003) will be presented at the 2025 San Antonio Breast Cancer Symposium, highlighting its focus on innovative cancer treatments [1][2] Company Overview - Oncotelic Therapeutics, Inc. was founded to develop transformative medicines for cancer patients, utilizing its PDAOAI platform and expertise in nanomedicines [1] - The company has a history dating back to 1988, originally formed as OXiGENE, Inc., and has undergone several name changes and reincorporations [5][6] Product Development - Sapu003 is a novel formulation of everolimus designed for intravenous use, addressing limitations of oral mTOR inhibitors such as poor bioavailability and dose-limiting toxicity [2] - The ongoing Phase 1 trial of Sapu003 targets hormone receptor-positive (HR⁺)/HER2⁻ metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET) [2] Clinical Trials and Collaborations - The studies related to Sapu003 are conducted in collaboration with Southern Oncology Clinical Research Unit (SOCRU), Ingenu CRO, and Medicilon, focusing on molecular biomarker discovery and pharmacokinetic modeling [4] - Accepted abstracts for presentation at the symposium include research on predictive biomarkers and pharmacokinetic rationale for Sapu003 [4] Market Context - The FDA has previously approved oral everolimus for advanced RCC and pancreatic NET, indicating a market for mTOR inhibitors in oncology [5] - The company aims to leverage its expertise to improve treatment outcomes, particularly for rare pediatric cancers [6][7]

Core Insights - Oncotelic Therapeutics Inc. is gaining attention for its innovative approach in the oncology market, particularly through its Deciparticle(TM) platform which enhances drug delivery and bioavailability [1][3] Industry Overview - The global oncology market is shifting towards advanced drug-delivery systems that improve efficacy, reduce toxicity, and enhance patient outcomes, addressing the limitations of traditional oral or IV drugs [2] - Recent advancements in nanomedicine are being recognized by regulatory bodies, indicating a trend towards endorsing nanocarrier-based delivery systems for complex drugs [2] Company Developments - Oncotelic's Deciparticle(TM) platform aims to transform existing cancer drugs into next-generation therapies by increasing their bioavailability and therapeutic index [3] - The advancement of Sapu-003, an Intravenous Deciparticle(TM) Everolimus (Afinitor(R)), into human trials demonstrates the company's commitment to innovation in drug delivery [3] - Oncotelic Therapeutics is focused on addressing high-unmet-need cancers and rare pediatric indications with its late-stage therapeutic candidates [4] Strategic Position - The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents [4] - Oncotelic owns 45% of GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, further strengthening Oncotelic's strategic position in oncology and rare disease therapeutics [4]

Core Insights - Nanobiotix (NBTX) is a clinical-stage nanomedicine company valued at $1.3 billion, focusing on innovative cancer treatment approaches with proprietary technology including NBTXR3 [1] Stock Performance - NBTX has shown exceptional price momentum, gaining 440% over the past year and 200.78% since a "Buy" signal was issued on August 27 [2][6] - The stock reached an all-time high of $27.77 in intraday trading on October 8 [4] - NBTX has made 13 new highs and gained 198.02% in the last month, with a Relative Strength Index (RSI) of 82.55 [7] Technical Indicators - Barchart indicates a 100% "Buy" opinion for NBTX, with a Weighted Alpha of +470.88 [7] - The stock has a technical support level around $25.96 [7] Revenue and Earnings Projections - Revenue is projected to grow by 643.31% this year and an additional 89.01% next year [7] - Earnings are estimated to increase by 79.86% this year and 235.61% next year [7]

Company Overview - Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products aimed at addressing high unmet needs in cancer and rare pediatric diseases [4][3] - The company is led by Dr. Vuong Trieu, who has a strong background in intellectual property with approximately 500 patent applications and 75 granted patents [3][4] Innovation and Technology - Oncotelic is leveraging advanced technologies such as AI, nanomedicine, and innovative clinical approaches to transform biotechnology and improve treatment options for cancer and rare diseases [3][4] - The company has a robust pipeline of therapeutic candidates that are in late-stage development, which is designed to address significant medical needs [4] Strategic Positioning - Oncotelic Therapeutics holds a 45% stake in GMP Bio, a joint venture that is developing its own pipeline of drug candidates, thereby enhancing Oncotelic's strategic position in oncology and rare disease therapeutics [4] - The company benefits from a strong intellectual property portfolio, which is critical for its competitive advantage in the biopharmaceutical industry [3][4]